

AMENDMENTS TO THE CLAIMS:

This listing of the claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1-24 (canceled)

25. (Currently amended) A cell expressing a multivalent composition for active idiotype immunotherapy produced according to a method comprising:

- a) providing:
 - i) malignant B cells isolated from a patient having a quasi-clonal B-cell lymphoma;
 - ii) at least one expression vector;
 - iii) an amplification vector comprising a recombinant oligonucleotide having a sequence encoding a first inhibitable enzyme operably linked to a heterologous promoter; and
 - iv) a T lymphoid parent cell line;
- b) isolating nucleic acid from said malignant cells, said nucleic acid comprising nucleotide sequences selected from the group consisting of nucleotide sequences encoding at least one V_H region and at least two V_L regions, nucleotide sequences encoding at least two V_H regions and at least one V_L region, and nucleotide sequences encoding at least two V_H regions and at least two V_L regions, wherein said at least two V_L regions differ by at least one idiotope, wherein said at least two V_H regions differ by at least one idiotope, and wherein said V_H and V_L regions are derived from immunoglobulin molecules expressed by said malignant cells;
- c) inserting said nucleic acid comprising nucleotide sequences encoding said V_H and V_L regions into said at least one expression vector ;
- d) introducing said at least one expression vector and said amplification vector into said parent cell line to generate one or more transformed cells;

e) growing said transformed cells in a first aqueous solution containing an inhibitor capable of inhibiting said first inhibitable enzyme wherein the concentration of said inhibitor present in said first aqueous solution is sufficient to prevent growth of said parent cell line; and

f) identifying a transformed cell capable of growth in said first aqueous solution, wherein said transformed cell capable of growth expresses a combination of V_H and V_L regions selected from the group consisting of at least one V_H region and at least two V_L regions, at least two V_H regions and at least one V_L region, and at least two V_H regions and at least two V_L regions, wherein said at least two V_L regions differ by at least one idiotope, wherein said at least two V_H regions differ by at least one idiotope, and wherein said V_H and V_L regions comprise a protein molecule,

wherein said multivalent composition comprises said expressed V_H and V_L regions.

26. (Previously presented) The composition of Claim 25, wherein nucleotide sequences encoding said V_H and V_L regions comprise at least two V_H and at least one V_L regions.

27. (Previously presented) The composition of Claim 25, wherein nucleotide sequences encoding said V_H and V_L regions comprise at least one V_H and at least two V_L regions.

28. (Currently amended) A cell expressing a multivalent composition for active idiotype immunotherapy produced according to a method comprising:

- a) providing:
 - i) malignant B cells isolated from a patient having a quasi-clonal B-cell lymphoma;
 - ii) at least one expression vector;
 - iii) an amplification vector comprising a first recombinant oligonucleotide having a sequence encoding a first

inhibitable enzyme operably linked to a heterologous promoter;

- iv) a selection vector comprising a second recombinant oligonucleotide having a sequence which encodes a selectable gene product; and
- v) a T lymphoid parent cell line;
- b) isolating nucleic acid from said malignant cells, said nucleic acid comprising nucleotide sequences selected from the group consisting of nucleotide sequences encoding at least one V_H region and at least two V_L regions, nucleotide sequences encoding at least two V_H regions and at least one V_L region, and nucleotide sequences encoding at least two V_H regions and at least two V_L regions, wherein said at least two V_L regions differ by at least one idiotope, wherein said at least two V_H regions differ by at least one idiotope, and wherein said V_H and V_L regions are derived from immunoglobulin molecules expressed by said malignant cells;
- c) inserting said nucleic acid comprising said nucleotide sequences encoding said V_H and V_L regions into said at least one expression vector;
- d) introducing said at least one expression vector, said amplification vector and said selection vector into said parent cell line to generate transformed cells;
- e) introducing said transformed cells into a first aqueous solution, said first aqueous solution requiring the expression of said selectable gene product for growth of said transformed cells;
- f) identifying at least one transformed cell capable of growth in said first aqueous solution;
- g) introducing said transformed cell capable of growth in said first aqueous solution into a second aqueous solution, said second aqueous solution comprising an inhibitor capable of inhibiting said first inhibitable enzyme, wherein the concentration of said inhibitor present in said second aqueous solution is sufficient to prevent growth of said parent cell line; and
- h) identifying at least one transformed cell capable of growth in said second aqueous solution, wherein said transformed cell capable of growth expresses a combination of V_H and V_L regions selected from the group consisting of at least one V_H

region and at least two V_L regions, at least two V_H regions and at least one V_L region, and at least two V_H regions and at least two V_L regions, wherein said at least two V_L regions differ by at least one idiotope, wherein said at least two V_H regions differ by at least one idiotope, and wherein said V_H and V_L regions comprise a protein molecule,

wherein said multivalent composition comprises said expressed V_H and V_L regions.

29. (Currently amended) A clone expressing a multivalent composition for active idiotype immunotherapy produced according to a method comprising:

- a) providing:
 - i) malignant B cells isolated from a patient having a quasi-clonal B-cell lymphoma;
 - ii) at least one expression vector;
 - iii) an amplification vector comprising a first recombinant oligonucleotide having a sequence encoding a first inhibitable enzyme operably linked to a heterologous promoter;
 - iv) a selection vector comprising a second recombinant oligonucleotide having a sequence which encodes a selectable gene product; and
 - v) a T lymphoid parent cell line;
- b) isolating nucleic acid from said malignant cells, said nucleic acid comprising nucleotide sequences selected from the group consisting of nucleotide sequences encoding at least one V_H region and at least two V_L regions, nucleotide sequences encoding at least two V_H regions and at least one V_L region, and nucleotide sequences encoding at least two V_H regions and at least two V_L regions, wherein said at least two V_L regions differ by at least one idiotope, wherein said at least two V_H regions differ by at least one idiotope, and wherein said V_H and V_L regions are derived from immunoglobulin molecules expressed by said malignant cells;
- c) inserting said nucleic acid comprising said nucleotide sequences encoding said V_H and V_L regions into said at least one expression vector;

d) introducing said at least one expression vector, said amplification vector and said selection vector into said parent cell line to generate transformed cells;

e) introducing said transformed cells into a first aqueous solution, said first aqueous solution requiring the expression of said selectable gene product for growth of said transformed cells;

f) identifying at least one individual clone of transformed cells capable of growth in said first aqueous solution;

g) introducing said individual clone capable of growth in said first aqueous solution into a second aqueous solution, said second aqueous solution comprising an inhibitor capable of inhibiting said first inhibitable enzyme, wherein the concentration of said inhibitor present in said first aqueous solution is sufficient to prevent growth of said parent cell line; and

h) identifying at least one individual clone capable of growth in said second aqueous solution, wherein said clone capable of growth expresses a combination of V_H and V_L regions selected from the group consisting of at least one V_H region and at least two V_L regions, at least two V_H regions and at least one V_L region, and at least two V_H regions and at least two V_L regions, wherein said at least two V_L regions differ by at least one idiotope, wherein said at least two V_H regions differ by at least one idiotope, wherein said V_H and V_L regions comprise a protein molecule,

wherein said multivalent composition comprises said expressed V_H and V_L regions.

30-32 (canceled)